Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
Apr 10, 2018 -- Study findings support the potential for plazomicin to address difficult-to-treat infections, including those caused by carbapenem-resistant Enterobacteriaceae -- SOUTH SAN FRANCISCO, Calif., April 10, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company develo...
Mar 22, 2018 SOUTH SAN FRANCISCO, Calif., March 22, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on March 20, 2018 the compensation committee of the Company's board of ...
Mar 21, 2018 -- Meeting planned for May 2, 2018 -- SOUTH SAN FRANCISCO, Calif., March 21, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Antimicrobial...
Mar 14, 2018 -- Company presentation scheduled for March 27, 2018 -- SOUTH SAN FRANCISCO, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced...
Mar 6, 2018 -- Company presentation scheduled for March 13, 2018 -- SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced...
Feb 27, 2018 -- Plazomicin New Drug Application (NDA) accepted by U.S. Food and Drug Administration (FDA);June 25, 2018 set as PDUFA action date -- -- Orally-administered antibacterial candidate C-Scape achieved positive top-line results in Phase 1 -- -- Confe...
Feb 21, 2018 SOUTH SAN FRANCISCO, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on February 20, 2018, the compensation committee of the Company's board of...
Feb 13, 2018 SOUTH SAN FRANCISCO, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will report its fourth quarter financial results on T...
Feb 7, 2018 -- Company presentation scheduled for February 15, 2018 at 9:30 a.m. ET -- SOUTH SAN FRANCISCO, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-n...
Jan 30, 2018 -- McPherson, Kansas facility compliance status amended to Voluntary Action Indicated (VAI) -- -- VAI status provides a clear regulatory path for potential approval of plazomicin out of McPherson facility -- SOUTH SAN FRANCISCO, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE)...
Page:
1
... NextLast
= add release to Briefcase